SPRUCE BIOSCIENCES INC
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
SPRB$46.67-5.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Additional · Accumulated Other · Total | ||||||
|---|---|---|---|---|---|---|
| Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders’ | ||||||
| Shares | Amount | Capital | Loss | Deficit | Equity | |
| Balance as of June 30, 2024 | 41,302,599 | $4 | $277,203 | $— | $(218,038) | $59,169 |
| Stock-based compensation | — | — | 1,140 | — | — | 1,140 |
| Net loss | — | — | — | — | (8,671) | (8,671) |
| Balance as of September 30, 2024 | 41,302,599 | $4 | $278,343 | $— | $(226,709) | $51,638 |
| Additional · Accumulated Other · Total | ||||||
|---|---|---|---|---|---|---|
| Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders’ | ||||||
| Shares | Amount | Capital | Loss | Deficit | Equity | |
| Balance as of January 1, 2024 | 41,029,832 | $4 | $273,737 | $— | $(197,232) | $76,509 |
| Exercise of common stock options | 120,328 | — | 180 | — | — | 180 |
| Issuance of common stock related to employee stock purchase plan | 118,534 | — | 52 | — | — | 52 |
| Issuance of common stock related to vesting of restricted stock units, net of tax withholdings | 33,905 | — | (13) | — | — | (13) |
| Stock-based compensation | — | — | 4,387 | — | — | 4,387 |
| Net loss | — | — | — | — | (29,477) | (29,477) |
| Balance as of September 30, 2024 | 41,302,599 | $4 | $278,343 | $— | $(226,709) | $51,638 |
| Additional · Accumulated Other · Total | ||||||
|---|---|---|---|---|---|---|
| Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders’ | ||||||
| Shares | Amount | Capital | Gain (Loss) | Deficit | Equity | |
| Balance as of June 30, 2023 | 40,710,692 | $4 | $271,540 | $(55) | $(174,928) | $96,561 |
| Stock-based compensation | — | — | 1,122 | — | — | 1,122 |
| Unrealized gain on available for sale securities | — | — | — | 52 | — | 52 |
| Net loss | — | — | — | — | (12,354) | (12,354) |
| Balance as of September 30, 2023 | 40,710,692 | $4 | $272,662 | $(3) | $(187,282) | $85,381 |
| Additional · Accumulated Other · Total | ||||||
|---|---|---|---|---|---|---|
| Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders’ | ||||||
| Shares | Amount | Capital | Gain (Loss) | Deficit | Equity | |
| Balance as of January 1, 2023 | 23,601,004 | $3 | $218,354 | $(558) | $(149,313) | $68,486 |
| Exercise of pre-funded warrants | 800,000 | — | 8 | — | — | 8 |
| Issuance of common stock related to employee stock purchase plan | 102,984 | — | 99 | — | — | 99 |
| Issuance of common stock related to vesting of restricted stock units, net of tax withholdings | 90,704 | — | (94) | — | — | (94) |
| Issuance of common stock and warrants, net of offering costs of $2,721 | 16,116,000 | 1 | 50,894 | — | — | 50,895 |
| Stock-based compensation | — | — | 3,401 | — | — | 3,401 |
| Unrealized gain on available for sale securities | — | — | — | 555 | — | 555 |
| Net loss | — | — | — | — | (37,969) | (37,969) |
| Balance as of September 30, 2023 | 40,710,692 | $4 | $272,662 | $(3) | $(187,282) | $85,381 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.